Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
18 hedge funds and large institutions have $1.27M invested in Evoke Pharma in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 5 closing their positions.
60% more capital invested
Capital invested by funds: $798K → $1.27M (+$477K)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0.65% more ownership
Funds ownership: 5.5% → 6.16% (+0.65%)
5% less funds holding
Funds holding: 19 → 18 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$240K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$85.9K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
+$34.4K |
| 4 |
Jane Street
New York
|
+$11.7K |
| 5 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
+$9.25K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$67K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$37K |
| 3 |
Renaissance Technologies
New York
|
-$13K |
| 4 |
Morgan Stanley
New York
|
-$7.1K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.83K |
EVOK Hedge Fund Activity: Q3 2019 in Review
18 of the 4,575 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q3 2019, worth a combined $1.27M — up 60% from $798K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of EVOK and 4 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.
The largest buyer was Vanguard Group, adding an estimated $240K. The largest seller was Virtu Financial, exiting entirely with an estimated $67K sold.
- 18 institutional investors held Evoke Pharma (EVOK) as of Q3 2019, down from 19 in Q2 2019.
- Funds reported $1.27M of Evoke Pharma stock for Q3 2019, up 60% quarter-over-quarter.
- 4 funds opened new Evoke Pharma positions in Q3 2019 and 5 closed out, a net change of -1 holder.
- The largest Evoke Pharma buyer in Q3 2019 was Vanguard Group, an estimated $240K added.
- The largest Evoke Pharma seller in Q3 2019 was Virtu Financial, an estimated $67K sold.
Based on aggregated 13F filings for Q3 2019.